Clinical trials: Genomic Testing
Hypertension
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
The principal aim of the study is to demonstrate that Rostafuroxin is able to induce a more pronounced reduction of arterial blood pressure respect to Losartan, in hypertensive patients carrying at least one of the pre-specified…
- Trial name
- NCT03217825
- Testing
- Rostafuroxin, Losartan
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- Windtree Therapeutics
Colo-rectal Cancer, Cancer Colon
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early.
- Conditions
- Colo-rectal Cancer, Cancer Colon, Cancer, Rectum, Neoplasms,Colorectal
- Trial name
- NCT03688906
- Where
- 30 sites in United States, Canada
- Volunteers
- 3,275 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Cancer
Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens
Purpose of the Protocol: To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents, for the purpose of selecting the most clinically appropriate anticancer therapy…
- Trial name
- NCT02749838
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Pharmatech
Circulating Tumor DNA, Cancer
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has…
- Conditions
- Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing
- Trial name
- NCT02620527
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Foundation Medicine
Colorectal Cancer
Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in subjects with colorectal cancer that have documented recurrence or no evidence…
- Trial name
- PASCAL (NCT03706248)
- Testing
- Blood Draw
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Clinical Genomics Pathology
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Non-small-cell Lung Cancer
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Planned study population consists of approximately 1500 adult patients with a/m NSCLC in Russia, in about 20 oncological centers (in each center it is expected to recruit about 75 patients) in different regions of Russia in order…
- Trial name
- NCT06245837
- Where
- 16 sites in Russia
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Lung Cancer Diagnosis
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine…
- Trial name
- PROACT-LUNG (NCT06122077)
- Testing
- blood draw
- Where
- 36 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Freenome Holdings Inc.
Non-Small Cell Lung Cancer
GEMINI-NSCLC: NSCLC Biomarker Study
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care…
- Trial name
- NCT05236114
- Testing
- Observation
- Where
- 58 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Tempus AI
Non-hematologic Cancer
Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
- Trial name
- NCT02586389
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Sequenom, Inc.
Cancer, Neoplasm Metastasis
FoundationOne™ Test Registry Study
This study is a prospective, multicenter, observational study to characterize utilization patterns of the FoundationOne™ test by oncologists under conditions of routine clinical practice in the US.
- Conditions
- Cancer, Neoplasm Metastasis, Tumor
- Trial name
- FMI Registry (NCT01851213)
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Foundation Medicine
Prostate Cancer
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
- Trial name
- PROCEDE-2000 (NCT02209584)
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
- Trial name
- NCT01954004
- Where
- United States
- Volunteers
- 1,270 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Cancer
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
- Trial name
- NCT05254834
- Testing
- Freenome Test
- Where
- 68 sites in United States
- Volunteers
- 7,435 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Newly-diagnosed Cancers, Non-cancer Controls
The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
- Trial name
- NCT05516927
- Testing
- Freenome Test
- Where
- 23 sites in United States
- Volunteers
- 788 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Colorectal Adenocarcinoma
Colvera for Detection of Disease Recurrence
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in CRC subjects who are undergoing surveillance for recurrence.
- Trial name
- NOVA (NCT03706235)
- Testing
- Blood draw (venipuncture)
- Where
- 12 sites in United States
- Volunteers
- 488 people
- Sponsor
- Clinical Genomics Pathology
Non-Small Cell Lung Cancer
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
The aim of this study is to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced lung cancer.
- Trial name
- NCT02906852
- Where
- 35 sites in United States
- Volunteers
- 264 people
- Sponsor
- Inivata
Prostate Cancer
Registry to Measure the Impact of Adding Genomic Testing
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- NCT02454595
- Testing
- Registry
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Colon Cancer
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint
The aim of this study is to enroll 785 eligible stage II colon cancer patients in order to validate the performance of ColoPrint in estimating 3-year relapse rate.
- Trial name
- PARSC (NCT00903565)
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 1,200 people
- Sponsor
- Agendia
Breast Cancer
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients
This multicenter, prospectively designed study examines whether the Prosigna score influences physician and patient adjuvant treatment selection over and above currently used prognostic factors.
- Trial name
- NCT02625935
- Where
- 4 sites in United States
- Volunteers
- 206 people
- Sponsor
- NanoString Technologies, Inc.